Company Filing History:
1 out of 1,744 
1 out of 5,089 
1 out of 157 
Years Active: 2020
Title: The Innovative Journey of Emmanuelle Clerin-Lachapelle
Introduction
Emmanuelle Clerin-Lachapelle, based in Paris, France, is a prominent inventor recognized for her significant contributions to the field of retinal degeneration research. With a remarkable patent to her name, she has been pivotal in advancing therapeutic methods that aim to treat degenerative diseases affecting the retina.
Latest Patents
Emmanuelle's most notable patent is titled "Synergistic combination of neuronal viability factors and uses thereof". This invention outlines a novel approach that combines short and long Rod-Derived Cone Viability Factors to improve neuronal viability. The implications of this patent are profound, as it provides a new avenue for treating retinal degenerative diseases, potentially enhancing vision and quality of life for affected individuals.
Career Highlights
Throughout her career, Emmanuelle has made significant strides in biomedical research. She has worked with esteemed institutions such as Inserm (French National Institute of Health and Medical Research), the Institut National De La Santé Et De La Recherche Médicale, and the Centre National De La Recherche Scientifique (CNRS). Her dedication to scientific exploration and innovation has earned her recognition in the medical community.
Collaborations
Emmanuelle's journey has been enriched by collaborations with renowned scientists such as Thierry Leveillard and John G. Flannery. These partnerships reflect her commitment to teamwork and interdisciplinary research, fostering an environment of shared knowledge and breakthrough discoveries in the realm of vision science.
Conclusion
In conclusion, Emmanuelle Clerin-Lachapelle represents the forefront of innovation in retinal health. Her work not only exemplifies the spirit of invention but also highlights the importance of collaboration in scientific endeavors. As she continues to push the boundaries of research, her contributions will undoubtedly pave the way for future advancements in the treatment of retinal degenerative diseases.